Ernexa Therapeutics announced that its lead cell therapy candidate, ERNA-101, combined with PD-1 blockade, achieved complete tumor clearance and 100% survival in preclinical ovarian cancer models. This breakthrough suggests ERNA-101 can effectively remodel the tumor microenvironment to activate immune responses, addressing the challenge of immunosuppressive tumors. The company plans to advance ERNA-101 into first-in-human clinical trials for advanced ovarian cancer and explore its use in other solid tumors with similar immune resistance. This development could significantly improve treatment outcomes and shareholder value.
US stock futures gained following a mixed market close and President Trump's approval of Nvidia's H200 AI chip sales to Chinese firms, although China has halted deliveries. Economic data showed a 0.5% rise in April retail sales and a slight increase ...
Sumitomo Forestry has finalized its acquisition of Tri Pointe Homes for $47 per share, making Tri Pointe a wholly owned subsidiary and delisting it from the NYSE. This deal expands Sumitomo Forestry's U.S. homebuilding presence to 18 states, deliveri...
Verde Resources Inc. announced its invitation to the GenZero Climate Summit 2026 in Singapore, a key event focused on advancing net zero solutions. The company aims to expand its presence in Singapore and Southeast Asia, leveraging its newly establis...
Boeing shares rose following Treasury Secretary Scott Bessent's indication of significant aircraft orders from China during President Trump's meeting with Chinese President Xi Jinping. The U.S.-China tariff dispute had previously halted Boeing delive...
INmune Bio announced that the FDA granted Fast Track designation to its drug XPro1595 for treating early Alzheimer's disease, including mild cognitive impairment and mild dementia stages. This designation aims to speed up the development and review p...
